AzTrials
AzTrials

AnxietyOptesStressPNCT02320370

Transcranial Electrical Stimulation in the Treatment of Acute Anxiety Induced by Stressful Life Events: A Pilot Study

A study testing NeuroConn DC Stimulator Plus tDCS in people with Anxiety, run by University of Eastern Finland.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The investigators examine the efficacy of two different transcranial direct current stimulation (tDCS) stimulation protocols in the treatment of acute anxiety in an open-label pilot study in patients who have faced severely stressful life events. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Anxiety
What is being tested?
NeuroConn DC Stimulator Plus tDCS
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
14 participants
Where
No sites listed yet
Study dates
Jan 2015to Mar 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age 18-65 years
  • Naïve to tDCS
  • Right-handed
  • Impact of Event Scale Scores ≥ 30

Who cannot join

  • Metal implants inside skull or eye
  • Severe skin lesions at the electrode placement area
  • History of epilepsy or previous seizures
  • Pregnant or breast-feeding
  • Pacemaker
  • History of intracerebral bleeding during the past six months
Show all 9Show fewer
  • Major psychiatric conditions according to the Structured Clinical Interview for DSM-IV Disorders, i.e., Lifetime diagnoses of bipolar mood disorder or psychotic disorder
  • DSM-IV diagnosis for one or more of the following conditions during the past six months: unipolar mood disorder, anxiety disorders, eating disorders, or substance dependence/abuse.
  • Use of psychotropic medication (i.e., antipsychotic and antidepressant medications, mood stabilizers, psychostimulants, hypnotics and tranquilizers) during the past six months

Trial locations and contacts

No sites are listed yet.

Soili M Lehto, MD, PhD contact

+358 44 717 2971

soili.lehto@kuh.fi

About this study

Official title: Optimizing Electrical Stimulation for Clinical Applications (the OptES Study): Severe Psychological Stress - a Pilot Study (OptES-Stress-pilot)

The investigators examine the efficacy of two different transcranial direct current stimulation (tDCS) stimulation protocols in the treatment of acute anxiety in an open-label pilot study in patients who have faced severely stressful life events.

Read the detailed description

Transcranial direct current stimulation (tDCS) is a novel neuromodulation method that has been observed to be promising in treatment of psychiatric disorders such as depression. Nevertheless, knowledge related to the treatment of psychological stress and its main symptom, anxiety, is very scarce. The investigators examine the efficacy of two different transcranial direct current stimulation (tDCS) stimulation protocols in the treatment of acute anxiety in an open-label pilot study in patients who have faced severely stressful life events.

Conditions
Anxiety
Being tested
NeuroConn DC Stimulator Plus tDCS
Medical subject headings
Anxiety Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • NeuroConn DC Stimulator Plus tDCSDevice

    transcranial electrical stimulation intervention with two experimental protocols

Study groups in NCT02320370
Study groupRoleWhat they receive
Treatment 1ExperimentalNeuroConn DC Stimulator Plus tDCS treatment protocol no 1
Receives: Device: NeuroConn DC Stimulator Plus tDCS
Treatment 2ExperimentalNeuroConn DC Stimulator Plus tDCS treatment protocol no 1
Receives: Device: NeuroConn DC Stimulator Plus tDCS

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Impact of Event Scale (Change in scores of event-related anxiety)

    Change in scores of event-related anxiety

    Measured: 12 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Dec 2014 (estimated)
  2. Study startJan 2015
  3. Primary completionDec 2015 (estimated)
  4. Study completionMar 2016 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
14 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02320370
Sponsor's protocol ID
OptES-Stress-pilot
Acronym
OptesStressP
Status last verified
Dec 2014
First submitted
16 Dec 2014
Last updated
19 Dec 2014
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing NeuroConn DC Stimulator Plus tDCS in people with Anxiety, run by University of Eastern Finland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 19 Dec 2014. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Soili M Lehto, MD, PhD (+358 44 717 2971, soili.lehto@kuh.fi), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Impact of Event Scale (Change in scores of event-related anxiety) (time frame: 12 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Dec 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in